Compare AU
Compare VHY vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Vanguard Australian Shares High Yield ETF (VHY) and the BetaShares Global Healthcare Currency Hedged ETF (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
VHY | DRUG | |
|---|---|---|
Popularity | Medium | Low |
Pearlers invested | 1,308 | 62 |
Median incremental investment | $1,013.50 | $897.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,482.59 | $1,908.00 |
Average age group | > 35 | 26 - 35 |
Key Summary
VHY | DRUG | |
|---|---|---|
Strategy | VHY.AX was created on 2011-05-23 by Vanguard. The fund's investment portfolio concentrates primarily on high dividend yield equity. Vanguard Australian Shares High Yield ETF seeks to track the return of the FTSE Australia High Dividend Yield Index before taking into account fees, expenses and tax. | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | BHP Group Ltd. (10.26 %) Commonwealth Bank of Australia (9.79 %) National Australia Bank Ltd. (6.83 %) | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) |
Top 3 industries | Financials (40.37 %) Materials (23.34 %) Energy (10.73 %) | Other (76.44 %) Communication Services (33.53 %) Health Care (23.45 %) |
Top 3 countries | Australia (99.89 %) China (0.11 %) | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) |
Management fee | 0.25 % | 0.57 % |
Key Summary
VHY | DRUG | |
|---|---|---|
Issuer | Vanguard | BetaShares |
Tracking index | FTSE Australia High Dividend Yield Index - AUD | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.25 % | 0.57 % |
Price | $75.06 | $8.04 |
Size | N/A | $185.024 million |
10Y return | 18.52 % | N/A |
Annual distribution yield (5Y) | 7.42 % | 1.96 % |
Market | ASX | ASX |
First listed date | 26/05/2011 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
VHY | DRUG | |
|---|---|---|
Popularity | Medium | Low |
Pearlers invested | 1,308 | 62 |
Median incremental investment | $1,013.50 | $897.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,482.59 | $1,908.00 |
Average age group | > 35 | 26 - 35 |
Pros and Cons
VHY | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
VHY | DRUG |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |